137 related articles for article (PubMed ID: 35882788)
1. Taurine Supplementation Inhibits the Expression of Atrogin-1 and MURF-1, Protein Degradation Marker Genes, in Skeletal Muscle of C26-Induced Cachexia Mouse Model.
Doss HM; Kim JY; Kim KS
Adv Exp Med Biol; 2022; 1370():129-136. PubMed ID: 35882788
[TBL] [Abstract][Full Text] [Related]
2. Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.
Yuan L; Han J; Meng Q; Xi Q; Zhuang Q; Jiang Y; Han Y; Zhang B; Fang J; Wu G
Oncol Rep; 2015 May; 33(5):2261-8. PubMed ID: 25760630
[TBL] [Abstract][Full Text] [Related]
3. IMB0901 inhibits muscle atrophy induced by cancer cachexia through MSTN signaling pathway.
Liu D; Qiao X; Ge Z; Shang Y; Li Y; Wang W; Chen M; Si S; Chen SZ
Skelet Muscle; 2019 Mar; 9(1):8. PubMed ID: 30922397
[TBL] [Abstract][Full Text] [Related]
4. Glycine administration attenuates skeletal muscle wasting in a mouse model of cancer cachexia.
Ham DJ; Murphy KT; Chee A; Lynch GS; Koopman R
Clin Nutr; 2014 Jun; 33(3):448-58. PubMed ID: 23835111
[TBL] [Abstract][Full Text] [Related]
5. A standardized herbal combination of Astragalus membranaceus and Paeonia japonica, protects against muscle atrophy in a C26 colon cancer cachexia mouse model.
Lee SB; Lee JS; Moon SO; Lee HD; Yoon YS; Son CG
J Ethnopharmacol; 2021 Mar; 267():113470. PubMed ID: 33068652
[TBL] [Abstract][Full Text] [Related]
6. Creatine supplementation in Walker-256 tumor-bearing rats prevents skeletal muscle atrophy by attenuating systemic inflammation and protein degradation signaling.
Cella PS; Marinello PC; Borges FH; Ribeiro DF; Chimin P; Testa MTJ; Guirro PB; Duarte JA; Cecchini R; Guarnier FA; Deminice R
Eur J Nutr; 2020 Mar; 59(2):661-669. PubMed ID: 30806774
[TBL] [Abstract][Full Text] [Related]
7. The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia.
Bonetto A; Rupert JE; Barreto R; Zimmers TA
J Vis Exp; 2016 Nov; (117):. PubMed ID: 27929469
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Stat3 activation suppresses caspase-3 and the ubiquitin-proteasome system, leading to preservation of muscle mass in cancer cachexia.
Silva KA; Dong J; Dong Y; Dong Y; Schor N; Tweardy DJ; Zhang L; Mitch WE
J Biol Chem; 2015 Apr; 290(17):11177-87. PubMed ID: 25787076
[TBL] [Abstract][Full Text] [Related]
9. Forkhead box O3 plays a role in skeletal muscle atrophy through expression of E3 ubiquitin ligases MuRF-1 and atrogin-1 in Cushing's syndrome.
Kang SH; Lee HA; Kim M; Lee E; Sohn UD; Kim I
Am J Physiol Endocrinol Metab; 2017 Jun; 312(6):E495-E507. PubMed ID: 28246104
[TBL] [Abstract][Full Text] [Related]
10. Development of a traditional Chinese medicine-based agent for the treatment of cancer cachexia.
Wu KC; Chu PC; Cheng YJ; Li CI; Tian J; Wu HY; Wu SH; Lai YC; Kao HH; Hsu AL; Lin HW; Lin CH
J Cachexia Sarcopenia Muscle; 2022 Aug; 13(4):2073-2087. PubMed ID: 35718751
[TBL] [Abstract][Full Text] [Related]
11. Dose-dependent effects of leucine supplementation on preservation of muscle mass in cancer cachectic mice.
Peters SJ; van Helvoort A; Kegler D; Argilès JM; Luiking YC; Laviano A; van Bergenhenegouwen J; Deutz NE; Haagsman HP; Gorselink M; van Norren K
Oncol Rep; 2011 Jul; 26(1):247-54. PubMed ID: 21503587
[TBL] [Abstract][Full Text] [Related]
12. Combined administration of fucoidan ameliorates tumor and chemotherapy-induced skeletal muscle atrophy in bladder cancer-bearing mice.
Chen MC; Hsu WL; Hwang PA; Chen YL; Chou TC
Oncotarget; 2016 Aug; 7(32):51608-51618. PubMed ID: 27323407
[TBL] [Abstract][Full Text] [Related]
13. Antioxidant supplementation accelerates cachexia development by promoting tumor growth in C26 tumor-bearing mice.
Assi M; Derbré F; Lefeuvre-Orfila L; Rébillard A
Free Radic Biol Med; 2016 Feb; 91():204-14. PubMed ID: 26708754
[TBL] [Abstract][Full Text] [Related]
14. Oral Treatment with the Ghrelin Receptor Agonist HM01 Attenuates Cachexia in Mice Bearing Colon-26 (C26) Tumors.
Villars FO; Pietra C; Giuliano C; Lutz TA; Riediger T
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28475119
[TBL] [Abstract][Full Text] [Related]
15. Evidence for cardiac atrophic remodeling in cancer-induced cachexia in mice.
Tian M; Asp ML; Nishijima Y; Belury MA
Int J Oncol; 2011 Nov; 39(5):1321-6. PubMed ID: 21822537
[TBL] [Abstract][Full Text] [Related]
16. Alantolactone ameliorates cancer cachexia-associated muscle atrophy mainly by inhibiting the STAT3 signaling pathway.
Shen Q; Kuang JX; Miao CX; Zhang WL; Li YW; Zhang XW; Liu X
Phytomedicine; 2022 Jan; 95():153858. PubMed ID: 34861585
[TBL] [Abstract][Full Text] [Related]
17. Aerobic and resistance training dependent skeletal muscle plasticity in the colon-26 murine model of cancer cachexia.
Khamoui AV; Park BS; Kim DH; Yeh MC; Oh SL; Elam ML; Jo E; Arjmandi BH; Salazar G; Grant SC; Contreras RJ; Lee WJ; Kim JS
Metabolism; 2016 May; 65(5):685-698. PubMed ID: 27085776
[TBL] [Abstract][Full Text] [Related]
18. Leucine-Rich Diet Improved Muscle Function in Cachectic Walker 256 Tumour-Bearing Wistar Rats.
Viana LR; Chiocchetti GME; Oroy L; Vieira WF; Busanello ENB; Marques AC; Salgado CM; de Oliveira ALR; Vieira AS; Suarez PS; de Sousa LM; Castelucci BG; Vercesi AE; Consonni SR; Gomes-Marcondes MCC
Cells; 2021 Nov; 10(12):. PubMed ID: 34943780
[TBL] [Abstract][Full Text] [Related]
19. Epigallocatechin-3-gallate effectively attenuates skeletal muscle atrophy caused by cancer cachexia.
Wang H; Lai YJ; Chan YL; Li TL; Wu CJ
Cancer Lett; 2011 Jun; 305(1):40-9. PubMed ID: 21397390
[TBL] [Abstract][Full Text] [Related]
20. Deacetylase inhibitors modulate the myostatin/follistatin axis without improving cachexia in tumor-bearing mice.
Bonetto A; Penna F; Minero VG; Reffo P; Bonelli G; Baccino FM; Costelli P
Curr Cancer Drug Targets; 2009 Aug; 9(5):608-16. PubMed ID: 19508174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
